Retail chatter around Klotho Neurosciences picked up late Thursday after the company said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202. The designation ...

Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...

Boosting Klotho protein levels in mice improves physical and cognitive aging, offering potential for future longevity ...

U.S. stock futures declined on Thursday after ending higher on Wednesday. Futures of major benchmark indices were trading ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

Klotho didn’t just protect their brains, the researchers concluded — it enhanced them. Experiments on more mice turned up similar results. “I just couldn’t believe it — was it true, ...

Klotho Neurosciences (KLTO) witnessed an astonishing 800% increase in stock value on June 9, 2025, after revealing positive results from pre-clinical studies. The company’s investigations ...

Klotho, the study showed, improved the cognitive performance and even the mobility of mice whose brains were riddled with clumps and tangles of toxic proteins that are hallmarks of dementia and ...